Kent, United Kingdom

Paul Barraclough

USPTO Granted Patents = 3 



Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Surrey, GB (2011)
  • Kent, GB (2012)

Company Filing History:


Years Active: 2011-2012

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Paul Barraclough: Innovator in Medical Chemistry

Introduction

Paul Barraclough is a notable inventor based in Kent, GB, recognized for his contributions to medical chemistry. He holds three patents that showcase his innovative approach to addressing medical challenges through chemical compounds.

Latest Patents

One of his latest patents focuses on the medical use of triazine derivatives. These compounds, particularly those where R is an optionally substituted alkyl, aralkyl, or heterocyclyl-alkyl group, demonstrate activity as sodium channel blockers or as antifolates. Additionally, he has disclosed some novel compounds where R is an aralkyl or heterocyclyl-alkyl. Another significant patent involves cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. This method aims to treat patients with cytokine dysregulation by administering a therapeutically effective dose of a compound of a specific general formula.

Career Highlights

Throughout his career, Paul Barraclough has worked with reputable organizations, including BTG International Limited and the University of Greenwich. His work in these institutions has contributed to advancements in medical treatments and therapies.

Collaborations

Paul has collaborated with notable colleagues such as Michael J. Leach and Laurence Harbige, enhancing the impact of his research and innovations.

Conclusion

Paul Barraclough's work exemplifies the intersection of chemistry and medicine, leading to significant advancements in therapeutic applications. His patents reflect a commitment to improving patient care through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…